APTOF · Aptose Biosciences Inc.
Substantial doubt about the company's ability to continue as a going concern.
“our ability to continue as a going concern; - our need to raise substantial additional capital in the near future and our ability to raise such funds when needed and on acceptable terms; - if a financing is completed, it may not be a large enough financing to fully fund the company's operations”View the 10-Q filed May 13, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Feb 26, 2025; bars on opposite sides are not compared.
The closing range uses available history since Jul 2, 2026; less than a full year is stored.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
APTOF
this stock
Aptose Biosciences Inc.
|
$4.31M | — | — | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.9%
- Net QoQ
- +200 sh
- Top holder
- DRW Securities, LLC
Performance
Raw-price comparisons begin at the captured split on Feb 26, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| APTOF | — | — | — | — | — |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | — | — | — | — | — |